Catalent today announced the acquisition from Vaccine Manufacturing and Innovation Centre UK Limited of a biologics development and manufacturing facility currently under construction near Oxford, U.K.
Catalent today announced the appointment of Manja Boerman, Ph.D., to the role of President, Cell & Gene Therapy. In this new role, Dr. Boerman will lead all of Catalent’s cell & gene therapy businesses worldwide.
Catalent today welcomed the news that DiaMedica Therapeutics has received U.S. FDA approval to commence Phase 2 clinical trials of its lead candidate, DM199, for chronic kidney disease.
Catalent today announced the appointment of Karen Flynn as President of Biologics and Chief Commercial Officer. Ms. Flynn has also joined the company’s Executive Leadership Team and will report to Alessandro Maselli, Catalent’s President and Chief Operating Officer.
Catalent today announced the completion of a $3.2 million expansion program at its consumer health manufacturing facilities in Strathroy, Canada and Sorocaba, Brazil.
